Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Atara Biotherap (NQ: ATRA )

18.61 USD -0.24 (-1.27%)
Official Closing Price Updated: 7:53 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 930,500
Open 18.83
Bid (Size) 18.44 (1)
Ask (Size) 18.70 (1)
Prev. Close 18.85
Today's Range 18.34 - 19.19
52wk Range 4.520 - 28.20
Shares Outstanding 43,949,486
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Atara Biotherapeutics Will Present Recent Advancements and Key Upcoming Milestones at the 39th Annual J.P. Morgan Healthcare Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA; the “Company”), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with... 
From Business Wire News Releases
Atara Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious... 
From Business Wire News Releases

Performance

YTD
-5.24%
-5.24%
1 Month
-14.04%
-14.04%
3 Month
+35.15%
+35.15%
6 Month
+33.79%
+33.79%
1 Year
+27.12%
+27.12%

More News

Read More
InvestorNewsBreaks – Atara Biotherapeutics Inc. (NASDAQ: ATRA) Secures $175M in Underwritten Public Offering
From InvestorBrandNetwork
Atara Biotherapeutics Provides Regulatory Update for Tab-Cel® for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
From Business Wire News Releases
Atara Biotherapeutics Announces Pricing of $175.0 Million Public Offering
From Business Wire News Releases
Atara Biotherapeutics Announces Proposed Offering of Common Stock
From Business Wire News Releases
Atara Biotherapeutics Presents First Preclinical Evaluation of ATA3219, a Next-Generation Allogeneic CD19 CAR T Cell Therapy, at the 62nd American Society of Hematology (ASH) Annual Meeting
From Business Wire News Releases
Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors
From Business Wire News Releases
10 Biggest Price Target Changes For Tuesday
Tags KROS ATRA CTB
From Benzinga
The Week Ahead In Biotech (Dec. 27-Jan. 2): Data Releases, Regulatory Filings To Move Stocks
Tags Pharma/Biotech Stocks / Equities
From Blogs - TalkMarkets
12 Healthcare Stocks Moving In Monday's After-Market Session
Tags OBLN STRO NURO
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.